Key facts
- It has raised $20.4M; the latest was Early Stage VC ($2.0M) in May 2025.
- Notable investors include Sofinnova Partners, CDTI Innvierte, Asabys Partners, BCN Health Booster, BStartup10.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Nuage Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuage Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuage Therapeutics
Developer of selective and potent drugs designed for intrinsically disordered targets. The company leverages proprietary assays to discover new drugs for the treatment of castration-resistant prostate cancer, biomolecular condensation, and chemical biology to develop selective inhibitors of intrinsically disordered proteins, enabling doctors to treat undruggable proteins involved in diseases with unmet medical needs.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 24
- Website
- nuagetx.com/
- Ownership
- Privately Held (backing)
Nuage Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuage Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuage Therapeutics in its N-PORT filings yet. We sweep new filings monthly.